Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol

Eugenia Morselli1,2,3,6, Lorenzo Galluzzi1,2,3,6, Oliver Kepp1,2,3, Alfredo Criollo1,2,3, Maria Chiara Maiuri1,2,3, Nektarios Tavernarakis4, Frank Madeo5, and Guido Kroemer1,2,3

1 INSERM, U848, F-94805 Villejuif, France
2 Institut Gustave Roussy, F-94805 Villejuif, France
3 Université Paris Sud-XI, F-94805 Villejuif, France
4 Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion GR-71110, Crete, Greece
5 Institute of Molecular Biosciences, University of Graz, A-8010 Graz, Austria
6 Equally contributed to this article

Running title: Autophagy and longevity
Key words: AMPK; Caenorhabditis elegans; IKK; mTOR; p53; Saccharomyces cerevisiae
Abbreviations: AMPK, AMP-activated protein kinase; ATG, autophagy-related; BH3, Bcl-2 homology; dsRNA, double-stranded RNA; eIF2α, eukaryotic translation initiation factor 2α; ER, endoplasmic reticulum; ERK, extracellular signal-regulated kinase; HIF-1, hypoxia-inducible factor 1; IKK, IκB kinase; IGF, insulin-like growth factor; IP6, inositol 1,4,5-trisphosphate; IP3, IP3, receptor; JNK, c-JUN N-terminal kinase; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; PI3K, phosphatidylinositol-3-kinase; RNAi, RNA interference; TOR, target of rapamycin.
Correspondence: Nektarios Tavernarakis, Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Vasilikou Vouton, PO Box 1385, Heraklion GR-71110, Crete, Greece; Frank Madeo, Institute of Molecular Biosciences, University of Graz, Humboldtstrasse 50, A-8010 Graz, Austria; Guido Kroemer, INSERM U848, Institut Gustave Roussy, PR1, 39 rue Camille Desmoulins, F-94805 Villejuif, France
Received: 12/15/09; accepted: 12/22/09; published on line: 12/23/09
E-mail: tavernarakis@imbb.forth.gr; frank.madeo@uni-graz.at; kroemer@orange.fr
Copyright: © Morselli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract: Although autophagy has widely been conceived as a self-destructive mechanism that causes cell death, accumulating evidence suggests that autophagy usually mediates cytoprotection, thereby avoiding the apoptotic or necrotic demise of stressed cells. Recent evidence produced by our groups demonstrates that autophagy is also involved in pharmacological manipulations that increase longevity. Exogenous supply of the polyamine spermidine can prolong the lifespan of (while inducing autophagy in) yeast, nematodes and flies. Similarly, resveratrol can trigger autophagy in cells from different organisms, extend lifespan in nematodes, and ameliorate the fitness of human cells undergoing metabolic stress. These beneficial effects are lost when essential autophagy modulators are genetically or pharmacologically inactivated, indicating that autophagy is required for the cytoprotective and/or anti-aging effects of spermidine and resveratrol. Genetic and functional studies indicate that spermidine inhibits histone acetylases, while resveratrol activates the histone deacetylase Sirtuin 1 to confer cytoprotection/longevity. Although it remains elusive whether the same histones (or perhaps other nuclear or cytoplasmic proteins) act as the downstream targets of spermidine and resveratrol, these results point to an essential role of protein hypoacetylation in autophagy control and in the regulation of longevity.
INTRODUCTION

Autophagy (from the Greek, “auto” oneself, “phagy” to eat) involves the sequestration and degradation by lysosomal enzymes of old, supernumerary, damaged or ectopic organelles and/or portions of the cytoplasm [1]. At least three forms of autophagy have been described – macroautophagy, microautophagy, and chaperone-mediated autophagy – that differ with respect to the mode of cargo delivery to lysosomes [2,3]. This article will focus on macroautophagy (herein referred to as autophagy), the most important catabolic pathway that cells employ for the turnover of long-lived proteins and organelles and also one of the most prominent cytoprotective mechanisms in eukaryotic cell biology [4].

During macroautophagy, the cytoplasmic material targeted to degradation is delivered to lysosomes upon sequestration within double-membraned vesicles that are called autophagosomes. The generation of the autophagosome begins with the nucleation and elongation of the so-called phagophore, an isolation membrane that likewise originates from the endoplasmic reticulum. The edges of the phagophore then merge, resulting in the formation of a bona fide double-membraned autophagosome, which next fuses with a lysosome to generate an auto(phago)lysosome. Finally, the luminal content as well as the inner membrane of the autophagolysosome (which together are known as “autophagic body”) are degraded by lysosomal hydrolases. The end products of these catabolic reactions are exported to the cytoplasm, where they can re-enter anabolic and/or bioenergetic metabolisms [2,3,5,6].

The biochemical cascade that executes autophagy has originally been characterized at a molecular level in yeast (Saccharomyces cerevisiae) [7,8]. Hundreds of studies in different model organisms including mammals have confirmed that the essential machinery of autophagic sequestration and execution is phylogenetically conserved, and hence involves the orthologs of a series of yeast genes that have been designated autophagy-related (ATG) genes [7,8]. Autophagy likewise occurs at low baseline levels in all cells to ensure the homeostatic turnover of long-lived proteins and organelles [4]. Moreover, autophagy is upregulated well beyond basal levels: (i) when cells need to mobilize intracellular nutrients, as occurring during glucose and/or amino acid deprivation, hypoxia or growth factor withdrawal [2,3]; and (ii) when cells rid themselves of potentially noxious cytoplasmic materials including damaged organelles, aggregates of misfolded proteins, or invading microbes [9,10].

The complex regulation of autophagy in response to stress

One of the key regulators of autophagy in human and murine cells is the mammalian target of rapamycin (mTOR, whose yeast ortholog is TOR) kinase, which suppresses autophagy in conditions of nutrient and growth factor repletion. Signal transducers including class I phosphatidylinositol-3-kinases (PI3Ks) and Akt link receptor tyrosine kinases to mTOR activation, thereby repressing autophagy in response to insulin, insulin-like growth factor (IGF) and other growth signals [11]. Activation of the mTOR complex 1 (mTORC1) – and hence repression of autophagy – can also be mediated by mitogen-activated protein kinases (MAPKs) including extracellular signal-regulated kinases (ERKs) [12], by Ras-dependent activation of the p90 ribosomal S6 kinase [13], as well as by the Wnt signaling pathway [14]. Other prominent regulators of autophagy include (but are not limited to): AMP-activated protein kinase (AMPK), which inhibits mTOR in response to reduced ATP levels [15]; eukaryotic translation initiation factor 2α (eIF2α), which responds to nutrient deprivation as well as to double-stranded RNA (dsRNA) [16], ERN1 (whose yeast ortholog is known as IRE1), an endoplasmic reticulum (ER)-associated protein possessing intrinsic kinase and endoribonuclease activities and playing an important role in the alteration of gene expression upon ER stress [10,17]; and c-Jun N-terminal kinase (JNK), which is involved in multiple signaling cascades activated by stressful conditions [18].

Our own work in this field has added to this list of autophagy regulators: members of the Bcl-2 protein family that contain a single Bcl-2 homology (BH) domain, the so-called BH3-only proteins, which displace (and hence derepress) the essential autophagy modulator Beclin 1 from inhibitory complexes with Bcl-2 or Bcl-XL [19,20]; Sirtuin 1, which responds to high NAD+ levels, de facto acting as a sensor of nutrient availability [21]; the oncosuppressor protein p53, which inhibits autophagy when present in the cytoplasm [22]; the IκB kinase (IKK) complex, which is also essential for the activation of NF-κB by stress [23,24]; as well as the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) at the level of the ER [20,25]. Finally, autophagy is positively regulated by the transcription factor activity of E2F1 [26], FoxO3a [27,28], NF-κB [29] and p53 [30,31], among others. The apical events of the phylogenetically ancient molecular pathway for autophagy involveULK1 and ULK2 (the mammalian orthologs of Atg1) as well as Beclin 1 (the human ortholog of Atg6). Beclin 1 functions as an allosteric activator of the class III PI3K hVps34 (which promotes
phagophore nucleation/elongation via its product phosphatidylinositol-3-phosphate), and is part of a highly dynamic multiprotein complex that can incorporate various autophagic stimulators (e.g., UVRAG, Bif-1/endophilin B1, Ambra 1) and/or inhibitors (e.g., Bcl-2, RUBICON) [32-36].

In synthesis, autophagy is connected to multiple stress pathways. In some cases, specific proteins and organelles are “tagged” for autophagic sequestration, implying that intrinsic features of the cargo determine its elimination by autophagy. This has been documented for proteotoxins [37-39], uncoupled mitochondria (a process that has been dubbed “mitophagy”) [40-42], peroxisomes (for which the term “pexophagy” has been introduced) [43]; damaged ER (which is eliminated by “reticulophagy”) [44]; and invading pathogens (which activate “xenophagy”) [45]. In many other instances, autophagy occurs in a rather unselective fashion and represents a general response of the cell that transits from baseline to induced, yet limited levels. It is tempting to speculate that this change from basal to upregulated autophagy may involve the activation of a general “switch” that can respond to multiple distinct stress-responsive and damage-sensing pathways. Complex molecular switches regulate the clear-cut separation between discrete cellular states including the transition from an undifferentiated to a more differentiated state, the advancement of the cell cycle, or the “decision” to activate the apoptotic cascade [46,47]. Usually, such switches integrate diverse signals that are transmitted through negative feedback loops (which maintain homeostasis and keep cells in a defined state) and positive feedback loops (which mark the rapid evolution between two states) [48]. There is abundant evidence that the induction of autophagy involves positive feedback loops. For example, we have documented (i) that autophagy induced by rapamycin (which inhibits mTOR) is accompanied by the degradation of p53 and the activation of IKK; (ii) that pharmacological inhibition of p53 with pifithrin-α leads to mTOR inhibition and IKK activation; and that (iii) transgene-enforced activation of IKK stimulates p53 degradation at the same time as it inhibits mTOR [22-24,49]. This implies that mTOR inhibition, IKK activation and the degradation of cytoplasmic p53 are cross-linked through a network of self-amplifying feedforward loops (Figure 1), although it remains elusive how this occurs in molecular terms.

**Figure 1. Molecular composition of the hypothetical autophagic switch.** Irrespective of the primary stress signal, a homogeneous response would be obtained by the independent activation of molecular complexes organized around the IkB kinase (IKK), cytoplasmic p53, mTOR and Beclin 1. Within these complexes (and perhaps others), proteins would undergo reversible post-translational modifications and/or shuttle from one complex to another, thereby determining the function of the integrator/switch that activates autophagy. Please note that the autophagic switch is expected to contain several positive feedback loops that determine its (in)activation.
**Autophagy as a cytoprotective and anti-aging mechanism**

Cells that are stressed and on the verge of death frequently manifest the cytoplasmic accumulation of autophagosomes and auto(phago)lysosomes, an observation that has been (mis)interpreted as if autophagy would contribute to the cellular suicide [50]. Thus, hundreds of papers have described “autophagic” (also dubbed “type 2”) cell death, a cell demise subroutine preceded by massive autophagic vacuolization that is morphologically distinct from apoptosis (“type 1”) and necrosis (“type 3”) [51-54]. Although “autophagic cell death” undoubtedly exists as a morphological entity [53], this only exceptionally (at least in mammalian models) reflects the execution of cells by autophagy [50]. Rather, autophagy most frequently constitutes a (sometimes futile) mechanism of cellular adaptation to a diverse range of adverse conditions including hypoglycemia, hypoxia, lack of essential amino acids, absence of obligate growth factors or sublethal damage to cytoplasmic organelles including mitochondria and the ER [4,55,56]. Accordingly, the genetic inhibition of to cytoplasmic organelles including mitochondria and other chronic inflammatory states [6,61-64]. Genetic and pharmacological manipulations designed to induce autophagy have been shown to protect cells against otherwise lethal damage in vitro [5,6]. Deficient autophagy is directly involved in a number of pathologies including neurodegenerative diseases, heart failure, hereditary myopathies, steatosis/steatohepatitis and other chronic inflammatory states [6,61-64]. Genetic and pharmacological manipulations designed to induce autophagy have been shown to protect cells against otherwise lethal damage in vitro [5,6].

**Autophagy favors the maintenance of high intracellular ATP levels** [22,65], increases the capacity of cells to resist metabolic stress (hypoxia combined with nutrient deprivation) [22,66], prevents genomic instability [60,67] and limits the accumulation of potentially toxic proteins including proteotoxins that are responsible for neurodegeneration [10,38]. From a physiological point of view, aging can be viewed as a continuous decline in cellular and organismal functions that (at least partially) reflects the accumulation of misfolded proteins, oxidized lipids, as well as mutated mitochondrial and nuclear DNA.

The sole regimen leading to lifespan extension in every organism tested to date is dietary restriction, a reduction of the organism's caloric intake not associated to malnutrition [68]. Dietary restriction is a potent inducer of autophagy in virtually all species including mammals [69-71]. In the nematode Caenorhabditis elegans, autophagy is required for lifespan prolongation mediated by caloric restriction [72-74] or p53 depletion [22,49,75-77]. Thus, worms undergoing dietary restriction do not live longer than control animals if concomitantly subjected to RNA interference (RNAi) against *atg* genes [72-74].

Rapamycin, which activates autophagy via inhibition of (m)TOR, has also been ascribed with prominent anti-aging properties, in various model organisms. However, rapamycin cannot extend the chronological lifespan (i.e., the time post-mitotic cells survive during the stationary phase [78]) of yeast mutants that lack functional Atg1, Atg7 or Atg11 [79]. In C. elegans, the beneficial effects of rapamycin on longevity are lost when the essential autophagy modulator BEC-1 (the worm ortholog of mammalian Beclin 1 and yeast Atg6) is knocked down [74]. Thus, autophagy is required for rapamycin-mediated lifespan extension and delay of chronological aging in yeast and nematodes. Although it has not been formally demonstrated that rapamycin prolongs the lifespan of mice by inducing autophagy, even the treatment of pre-aged, genetically heterogeneous (out-bred) mice has been shown to increase longevity [80]. In mice, rapamycin avoids the age-related decline in hematopoietic stem cells function [81], an anti-senescence effect that has also been described in vitro [82,83].

Altogether, these results suggest that whole-body induction of autophagy by pharmacological agents may prolong the healthy lifespan, at least in laboratory conditions, supporting the idea that autophagy does not only confer cytoprotection but that it also has anti-aging effects at the organismal level.

**Autophagy mediates lifespan extension by resveratrol**

Driven by the aforementioned considerations, we launched the working hypothesis that autophagy constitutes (one of) the major mechanism(s) through which longevity-extending drugs operate. We thus studied whether resveratrol, a well-studied anti-aging agent [84], would extend the lifespan of model organisms via the induction of autophagy. Although it also affects mitochondrial functions [85], resveratrol prominently acts as an allostERIC activator of Sirtuin 1, a phylegenetically conserved deacetylase that senses the NAD+/NADH ratio [84]. Resveratrol increases the longevity of yeast, nematodes, and flies (Drosophila melanogaster) and also exerts anti-aging effects on mice kept on a high-fat diet [84,86]. Circumstantial evidence indicates that resveratrol can induce autophagy in yeast (although this was attributed to the oxidation of mitochondrial lipids [87]) and in human cancer cells (in
which resveratrol-induced autophagy often precedes
cell death [88]). Sirtuin 1 is the first protein that has
been demonstrated to prolong lifespan in yeast (and
then in animals including *C. elegans* and flies) [89], and
has also been shown to trigger autophagy in human and
murine cultured cells [90].

We confirmed that Sirtuin 1 overexpression increased
the autophagic flux in human cancer cells *in vitro*, and
that this effect was abolished by the addition of EX527,
a pharmacological inhibitor of its catalytic activity
[91,92]. Similarly, a transgene coding for SIR-2.1 (the
*C. elegans* ortholog of human Sirtuin 1) caused
autophagy in nematodes, suggesting that the link
between Sirtuin 1 activation and autophagy is
evolutionarily conserved [91,92]. Importantly, Sirtuin 1
was required for the induction of autophagy by nutrient
depivation (that was achieved by culturing cells in the
absence of serum, amino acids and glucose) but not by
other stimuli. Thus, in human cells, the depletion (by
RNAi) or inhibition (with EX527) of Sirtuin 1 fully
prevented the pro-autophagic effects of nutrient
starvation, yet failed to affect the stimulation of
autophagy by mTOR inhibition (with rapamycin), p53
inhibition (with pifithrin-α) or ER stress (triggered by
the addition of tunicamycin). Similarly, loss-of-function
mutations of *sir-2.1* abolished autophagy induced by
caloric restriction but not that promoted by rapamycin
or tunicamycin in *C. elegans* [91,92]. Transgenic
overexpression of *sir-2.1* increased the median and
maximum lifespan of nematodes as compared to non-
transgenic control strains with the same genetic
background. This gain in longevity was lost when the
essential autophagic modulator BEC-1 was depleted by
RNAi [91,92]. RNAi-mediated knockdown of the
*C. elegans* p53 ortholog CEP-1, a manipulation that
extends longevity through the stimulation of autophagy
[77], failed to further ameliorate the beneficial effects of
*sir-2.1* over-expression on longevity [91,92]. This
epistatic analysis suggests that SIR-2.1 accumulation
and CEP-1 depletion extend lifespan through a common
final pathway that relies on the induction of autophagy.

Another genetic intervention designed to indirectly
activate Sirtuin 1 (or its worm ortholog SIR-2.1)
consists in the transgenic overexpression of the gene
coding for the pyrazinamidase/nicotinamidase PNC-1,
which depletes nicotinamide, a negative regulator of
Sirtuin 1/SIR-2.1. Transgenic overexpression of *pnc-1*
did indeed induce autophagy in worms, and this
response was abolished by RNAi-mediated depletion of
SIR-2.1. Accordingly, the longevity-extending effects of
PNC-1 were lost upon the knockdown of SIR-2.1, as
well as upon that of either of the two essential
autophagy modulators BEC-1 or ATG-5 [77]. Thus,
both the overexpression and the metabolic activation of
Sirtuin 1/SIR-2.1 increase lifespan through the
induction of autophagy.

Next, we investigated whether resveratrol would induce
autophagy in *C. elegans* via the activation of SIR-2.1.
Addition of resveratrol to the worm culture medium did
indeed stimulate autophagy, and this effect was lost
upon RNAi-mediated depletion of SIR-2.1. Similarly,
resveratrol reduced the aging-associated mortality of
*C. elegans*, unless the products of *sir-2.1* or *bec-1* were
knocked down [77]. We concluded from these
experiments that resveratrol prolongs lifespan in human
and nematode cells by inducing autophagy, which
results from resveratrol-mediatedactivation of Sirtuin 1/SIR-2.1 (rather than from an off-target effect).

**Autophagy mediates lifespan extension by spermidine**

Driven by the fact that the intracellular level of
polyamines declines in (otherwise healthy) aging
humans [93], we investigated whether the polyanime
spermidine display anti-aging properties. To address
this question, we first took advantage of a yeast strain
that is deficient in the ornithine decarboxylase SPE1,
which catalyzes the first step of polyanime biosynthesis.
In chronological aging experiments, Δspe1 yeast cells
exhibited an increased mortality (and hence a shortened
lifespan), which could be restored to normal levels by
supplementation with low doses (0.1 mM) of
spermidine or its precursor putrescine [94].
Surprisingly, we found that higher concentrations of
spermidine were able to increase the lifespan of wild
type yeast cells with different genetic backgrounds.
Thus, both chronological aging (which constitutes a
model of post-mitotic aging) and replicative aging
(which constitutes a model of stem cell aging) of yeast
cells were significantly inhibited by spermidine
supplementation. Lifespan prolongation in spermidine-
treated yeast cells could be correlated with the reduced
acetylation of several lysine residues located at the N-
terminal tail of histone H3 (i.e., Lys9, Lys14 and
Lys18) [94]. Deletion of *sir2* (the yeast ortholog of
*Sirtuin 1*) or any other sirtuin did not affect the ability
of spermidine to extend chronological lifespan. Instead,
epistatic analyses revealed that the anti-aging effect of
spermidine was phenocopied by the knockout of histone
acetylases, which hence were shown to regulate the
same longevity-increasing pathway than spermidine
does [94]. Moreover, spermidine efficiently inhibited
general histone acetylase activity in extracts from
purified yeast and mammalian nuclei in an *in vitro*
assay [94]. These results suggest that spermidine acts
differently from resveratrol. Thus, while the former
inhibits histone acetylase(s), the latter stimulates the deacetylase activity of Sirtuin 1. However, formal evidence that the (de)acetylation of histones rather than that of other proteins (either in the nucleus or in the cytoplasm) account for the anti-aging properties of spermidine is still missing.

Microarray profiling of spermidine-treated yeast cells revealed the transcriptional activation of several autophagy genes including atg7, atg11 and atg15, and we indeed found that spermidine induces autophagy in yeast cells. Similarly, spermidine was highly efficient in upregulating the autophagic pathways when it was added to the culture medium or solid food of C. elegans or D. melanogaster, respectively. The same concentrations of spermidine that exerted pro-autophagic effects also had a marked lifespan-extending effect on yeast, nematodes and flies. The genetic inhibition of essential ATG genes (i.e., knockout of atg7 in yeast and flies, RNAi-mediated silencing of bec-1 in nematodes) abrogated longevity extension induced by spermidine, indicating this polyamine can prolong lifespan by the induction of autophagy [94].

Open questions

The aforementioned results indicate that resveratrol and spermidine can prolong the lifespan of model organisms through the induction of autophagy (Figure 2). In addition, our work raises at least three issues that must be addressed by future investigation.

First, do resveratrol and spermidine extend longevity by acting on the same molecular pathway? While resveratrol can prolong lifespan through the activation of the deacetylase activity of Sirtuin 1 (or its non-mammalian equivalents SIR2 in yeast and SIR-2.1 in C. elegans), spermidine inhibits the general histone acetylase activity of yeast and mouse liver extracts. Clearly, histone (de)acetylation has been recognized as an important epigenetic regulator of longevity [95,96]. However, a fraction of Sirtuin 1 is present in the cytoplasm, from where it can directly deacetylate essential autophagic proteins (including ATG5, ATG7 and ATG8/LC3) [90], suggesting that (at least part of) the pro-autophagic effects of resveratrol derive from extranuclear, transcription-independent events. It will be important to know whether polyamines (like spermidine) and Sirtuin 1 activators (including resveratrol) can exert additive or synergistic effects on autophagy and longevity or whether these agents exactly activate the same molecular pathway. Moreover, the precise mechanisms by which spermidine and resveratrol control the autophagic switch awaits further exploration. Careful mechanistic and epistatic analyses are required to address this problem.

Second, do all longevity-prolonging manipulations induce autophagy? And is autophagy required for all such intervention to extend lifespan? Current results clearly indicate that autophagy is indispensable for the anti-aging action of rapamycin, resveratrol and spermidine. Moreover, it has been suggested that autophagy is required for longevity extension by dietary restriction in C. elegans, although this has not been tested for all caloric restriction protocols [73]. It remains an ongoing conundrum whether an increased level of autophagy is required in C. elegans for longevity extension conferred by the deficiency of GTPase RHEB-1 [97], the transcription faction hypoxia-inducible factor 1 (HIF-1) [98] and its negative regulator VHL-1 [99], the ubiquitin ligase WWP-1 [100], as well as the chaperones CCT4 and CCT6 [101]. A positive response to this question could establish a new paradigm in longevity research.
Third, and most important, can the data that we discuss here, which have mostly been obtained in simple model organisms and in laboratory conditions (where, for instance, the immunosuppressive side effects of resveratrol are certainly less incisive), be extrapolated to humans and to real life? Although rapamycin and polyamines can increase lifespan in mice [80,102], resveratrol only extends the longevity of mice that are kept on a high-caloric diet [86]. Clearly, rapamycin and resveratrol can induce autophagy in vivo, in mice [23,24,103]. However, it is thus far unknown whether there is indeed a cause-effect relationship between increased autophagy and healthy aging in mammals and in particular in humans. Such a causal relationship would revolutionize the entire field of aging research.

ACKNOWLEDGMENTS

NT is supported by grants from EMBO, the European Research Council (ERC) and the European Commission Coordination Action ENINET (contract number LSHM-CT-2005-19063). GK is supported by the Ligue Contre le Cancer (Equipe labellisée), Agence Nationale pour la Recherche (ANR), European Commission (Apo-Sys, ChemoRes, ApopTrain, Active p53), Fondation pour la Recherche Médicale (FRM), Institut National du Cancer (INCa) and Cancéropôle Ile-de-France. EM is funded by a Ph.D. student grant from ApopTrain. LG is supported by the Apo-Sys consortium of the European Union. OK is funded by FRM.

CONFLICT OF INTERESTS STATEMENT

The authors of this manuscript have no conflict of interests to declare.

REFERENCES

1. Martinou JC, Kroemer G. Autophagy: evolutionary and pathophysiological insights. Biochim Biophys Acta. 2009; 1793: 1395-1396.
2. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009; 43: 67-93.
3. Mizushima N, Klionsky D.J. Protein turnover via autophagy: implications for metabolism. Annu Rev Nutr. 2007; 27: 19-40.
4. Galluzzi L, Vicencio JM, Kepp O, Tasdemir E, Maiuri MC, Kroemer G. To die or not to die: that is the autophagic question. Curr Mol Med. 2008; 8: 78-91.
5. Kundu M, Thompson CB. Autophagy: basic principles and relevance to disease. Annu Rev Pathol. 2008; 3: 427-455.
6. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008; 132: 27-42.
7. Klionsky DJ, Cregg JM, Dunn WA, Jr., Emr SD, Sakai Y, Sandoval IV, Sibirny A, Subramani S, Thumm M, Veenhuis M, Oh umi Y. A unified nomenclature for yeast autophagy-related genes. Dev Cell. 2003; 5: 539-545.
8. Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y. Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nat Rev Mol Cell Biol. 2009; 10: 458-467.
9. Virgin HW, Levine B. Autophagy genes in immunity. Nat Immunol. 2009; 10: 461-470.
10. Madeo F, Eisenberg T, Kroemer G. Autophagy for the avoidance of neurodegeneration. Genes Dev. 2009; 23: 2253-2259.
11. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T, Thompson CB. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell. 2005; 120: 237-248.
12. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfo P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005; 121: 179-193.
13. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A. 2004; 101: 13489-13494.
14. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006; 126: 955-968.
15. Poels J, Spasic MR, Callaerts P, Norga KK. Expanding roles for AMP-activated protein kinase in neuronal survival and autophagy. Bioessays. 2009; 31: 944-952.
16. Tallozy C, Jiang W, Virgin HW, Leib DA, Scheuner D, Kaufman RJ, Eskelinen EL, Levine B. Regulation of starvation- and virus-induced autophagy by the elF2alpha kinase signaling pathway. Proc Natl Acad Sci U S A. 2002; 99: 190-195.
17. Hetz C, Thienel P, Matus S, Nassif M, Court F, Kiffin R, Martinez G, Cuervo AM, Brown RH, Glimcher LH. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 2009; 23: 2294-2306.
18. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell. 2008; 30: 678-688.
19. Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, Tasdemir E, Pierron G, Troulinaki K, Tavernarakis N, Hickman JA, Geneste O, Kroemer G. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J. 2007; 26: 2527-2539.
20. Vicencio JM, Ortiz C, Criollo A, Jones AW, Kepp O, Galluzzi L, Joza N, Vitale I, Morselli E, Taillier M, Castedo M, Maiuri MC, Molgo J, et al. The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death Differ. 2009; 16: 1006-1017.
21. Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, Maiuri MC, Kroemer G. Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta. 2009; 1793: 1524-1532.
22. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D’Amelio M, Criollo A, Morselli E, Zhu C, Harper F, Nannmark U, Samara C, Pinton P, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol. 2008; 10: 676-687.
23. Criollo A, Senovilla L, Authier H, Maiuri MC, Morselli E, Vitale I, Kepp O, Tasdemir E, Galluzzi L, Shen S, Taillier M, Delahaye N, Tesniere A, et al. The Ikk complex contributes to the induction of autophagy. EMBO J. 2010; In press.
24. Cirollo A, Senovilla L, Authier H, Maiuri MC, Morselli E, Vitale I, Kepp O, Tasdemir E, Galluzzi L, Shen S, Tailler M, Delahaye N, Tesniere A, et al. IKK connects autophagy to major stress pathways. Autophagy. 2010; In press.

25. Cirollo A, Maiuri MC, Tasdemir E, Vitale I, Fiebig AA, Andrews D, Molgo J, Diaz J, Lavandero S, Harper F, Pierron G, di Stefano D, Rizzuto R, et al. Regulation of autophagy by the inositol trisphosphate receptor. Cell Death Differ. 2007; 14: 1029-1039.

26. Polager S, Ofir M, Ginsberg D. E2F1 regulates autophagy and the transcription of autophagy genes. Oncogene. 2008; 27: 4860-4864.

27. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, Burden SJ, Di Lisi R, Sandri C, Zhao J, Goldberg AL, Schiaffino S, Sandri M. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 2007; 6: 458-471.

28. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH, Goldberg AL. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007; 6: 472-483.

29. Copetti T, Bertoli C, Dalla E, Demarchi F, Schneider C. p65/RelA modulates BECN1 transcription and autophagy. Mol Cell Biol. 2009; 29: 2594-2608.

30. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009; 458: 1127-1130.

31. Voussen KH, Ryan KM. p53 and metabolism. Nat Rev Cancer. 2009; 9: 691-700.

32. Pattingre S, Tassa A, Xu Q, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005; 122: 927-939.

33. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crossstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol. 2007; 8: 741-752.

34. Matsunaga K, Saitoh T, Tabata K, Omori H, Satoh T, Kurotobi N, Maejima I, Shirahama-Noda K, Ichimura T, Isobe T, Akira S, Noda T, Yoshimori T. Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat Cell Biol. 2008; 11: 385-397.

35. Zhong Y, Wang QJ, Li X, Yan Y, Backer JM, Chait BT, Heintz N, Yue Z. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. Nat Cell Biol. 2009; 11: 468-476.

36. Maiuri MC, Cirollo A, Kroemer G. Crossstalk between apoptosis and autophagy within the Beclin 1 interactome. Embo J. 2010; In press.

37. Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH, Jaehress L, Fleming A, Pask D, Goldsmith P, O'Kane CJ, Floto RA, Rubinstein DC. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat Chem Biol. 2008; 4: 295-305.

38. Rubinstein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov. 2007; 6: 304-312.

39. Ravikumar B, Sarkar S, Rubinstein DC. Clearance of mutant aggregate-prone proteins by autophagy. Methods Mol Biol. 2008; 445: 195-211.

40. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008; 183: 795-803.

41. Tolkovsky AM. Mitophagy. Biochim Biophys Acta. 2009; 1793: 1508-1515.

42. Zhang J, Kundu M, Ney PA. Mitophagy in mammalian cells: the reticulocyte model. Methods Enzymol. 2009; 452: 227-245.

43. Farre JC, Manjithaya R, Mathewson RD, Subramani S. PpAtg30 targets peroxisomes for turnover by selective autophagy. Dev Cell. 2008; 14: 365-376.

44. Tasdemir E, Maiuri MC, Tajeddine N, Vitale I, Cirollo A, Vicenzo JM, Hickman JA, Genoise O, Kroemer G. Cell cycle-dependent induction of autophagy, mitophagy and reticulocytosis. Cell Cycle. 2007; 6: 2253-2267.

45. Levine B. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. Cell. 2005; 120: 159-162.

46. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004; 116: 205-219.

47. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007; 87: 99-163.

48. Sauvage JP. (2001). Molecular Machines & Motors (Structure and Bonding) (New York: Springer-Verlag).

49. Tasdemir E, Chiara Maiuri M, Morselli E, Cirollo A, D’Amelio M, Djavaheris-Mergny M, Cecconi F, Tavernarakis N, Kroemer G. A dual role of p53 in the control of autophagy. Autophagy. 2008; 4: 810-814.

50. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol. 2008; 9: 1004-1010.

51. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitovgal L, Kroemer G. Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 2007; 14: 1237-1243.

52. Galluzzi L, Jozza N, Tasdemir E, Maiuri MC, Hengartner M, Abrams JM, Tavernarakis N, Penninger J, Madeo F, Kroemer G. No death without life: vital functions of apoptotic effectors. Cell Death Differ. 2008; 15: 1113-1123.

53. Kroemer G, Galluzzi L, Vandenameele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009; 16: 3-11.

54. Kroemer G, Tolkovsky AM, Zakeri Z. Elan vital, elan letal: one life but multiple deaths. Cell Death Differ. 2008; 15: 1089-1090.

55. Galluzzi L, Morselli E, Vicenzo JM, Kepp O, Jozza N, Tajeddine N, Kroemer G. Life, death and burial: multifaceted impact of autophagy. Biochem Soc Trans. 2008; 36: 786-790.

56. Vicenzo JM, Galluzzi L, Tajeddine N, Ortiz C, Cirollo A, Tasdemir E, Morselli E, Ben Younes A, Maiuri MC, Lavandero S, Kroemer G. Senescence, apoptosis or autophagy? When a damaged cell must decide its path—a mini-review. Gerontology. 2008; 54: 92-99.

57. Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Metivier D, Meley D, Souquere S, Yoshimori T, Pierron G, Codogno P, Kroemer G. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol. 2005; 25: 1025-1040.

58. Gonzalez-Polo RA, Boya P, Pauleau AL, Jallil A, Larochette N, Souquere S, Eskelinen EL, Pierron G, Saftig P, Kroemer G. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci. 2005; 118: 3091-3102.

59. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J, Mazure NM. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3

www.impactaging.com

968 AGING, December 2009, Vol.1 No.12
and BNIP3L via their BH3 domains. Mol Cell Biol. 2009; 29: 2570-2581.

60. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinaz C, Dipala RS, Karantza-Wadsworth V, White E. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2009; 137: 1062-1075.

61. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008; 451: 1069-1076.

62. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, Cuervo AM, Czaja MJ. Autophagy regulates lipid metabolism. Nature. 2009; 458: 1131-1135.

63. Fortunato F, Kroemer G. Impaired autophagosome-lysosome fusion in the pathogenesis of pancreatitis. Autophagy. 2009; 5: 850-853.

64. Fortunato F, Burgers H, Bergmann F, Rieger P, Buchler MW, Kroemer G, Werner J. Impaired autolysosome formation correlates with Lamp-2 depletion: role of apoptosis, autophagy, and necrosis in pancreatitis. Gastroenterology. 2009; 137: 350-360, 360 e351-355.

65. Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN, Gilpin C, Levine B. Autophagy gene-dependent clearance of apoptotic cells during embryonic development. Cell. 2007; 128: 931-946.

66. Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S, White E. Autophagy mitigates metabolic stress and genome damage in mammalian tumorigenesis. Genes Dev. 2007; 21: 1621-1635.

67. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, Chen G, Jin S, White E. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 2007; 21: 1367-1381.

68. Masoro EJ. Caloric restriction and aging: controversial issues. J Gerontol A Biol Sci Med Sci. 2006; 61: 14-19.

69. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004; 6: 463-477.

70. Vijg J, Campisi J. Puzzles, promises and a cure for ageing. Nature. 2008; 454: 1065-1071.

71. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Czurzen C, Simmons HA, kemnitz JW, Weindruch R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009; 325: 201-204.

72. Jia K, Levine B. Autophagy is required for dietary restriction-mediated life span extension in C. elegans. Autophagy. 2007; 3: 597-599.

73. Greer EL, Brunet A. Different dietary restriction regimens extend lifespan by both independent and overlapping genetic pathways in C. elegans. Aging Cell. 2009; 8: 113-127.

74. Hansen M, Chandra A, Miltic LL, Onken B, Driscoll M, Kenyon C. A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS Genet. 2008; 4: e24.

75. Tasdemir E, Galluzzi L, Maiuri MC, Criollo A, Vitale I, Hangen E, Modjtabadi N, Kroemer G. Methods for assessing autophagy and autophagic cell death. Methods Mol Biol. 2008; 445: 29-76.

76. Tasdemir E, Maiuri MC, Orhon I, Kepp O, Morselli E, Criollo A, Kroemer G. p53 represses autophagy in a cell cycle-dependent fashion. Cell Cycle. 2008; 7: 3006-3011.

77. Tavernarakis N, Pasparaki A, Tasdemir E, Maiuri MC, Kroemer G. The effects of p53 on whole organism longevity are mediated by autophagy. Autophagy. 2008; 4: 870-873.

78. Fabrizio P, Longo VD. The chronological life span of Saccharomyces cerevisiae. Aging Cell. 2003; 2: 73-81.

79. Alvers AL, Wood MS, Hu D, Kaywell AC, Dunn WA, Jr., Aris J. Autophagy is required for extension of yeast chronological life span by rapamycin. Autophagy. 2009; 5: 847-849.

80. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009; 460: 392-395.

81. Chen C, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal. 2009; 2: ra75.

82. Demidenko ZN, Zubova SG, Bukreeva EL, Pospelov VA, Pospelov TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle. 2009; 8: 1888-1895.

83. Demidenko ZN, Blagosklonny MV. At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. Cell Cycle. 2009; 8: 1901-1904.

84. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5: 493-506.

85. Tinofer I, Bernhard D, Senfter M, Anethé G, Loefler M, Kroemer G, Kofler R, Cordsa A, Greil R. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. Faseb J. 2001; 15: 1613-1615.

86. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pestell PJ, Poosala S, Becker KG, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006; 444: 337-342.

87. Kissova I, Deffieu M, Samokhalvalov V, Velours G, Bessoule JJ, Manon S, Camougrand N. Lipid oxidation and autophagy in yeast. Free Radic Biol Med. 2006; 41: 1655-1661.

88. Scarlett F, Maffei R, Beau I, Codogno P, Ghidoni R. Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. Cell Death Differ. 2008; 15: 1318-1329.

89. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature. 2009; 460: 587-591.

90. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Brunes NE, Tsokos M, Alt FW, Finkel T. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A. 2008; 105: 3374-3379.

91. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, Criollo A, Galluzzi L, Malik SA, Vitale I, Michaud M, Maffe D, Tavernarakis N, et al. Caloric restriction and resveratrol prolong longevity via the Sirtuin-1-dependent induction of autophagy. Cell Death Dis. 2010; In press.

92. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, Criollo A, Galluzzi L, Malik SA, Vitale I, Michaud M, Maffe D, Tavernarakis N, et al. The life span-prolonging effect of Sirtuin-1 is mediated by autophagy. Autophagy. 2010; In press.

93. Scalabrino G, Ferolli ME. Polyamines in mammalian ageing: an oncological problem, too? A review. Mech Ageing Dev. 1984; 26: 149-164.

94. Eisenberg T, Knauer H, Schauer A, Buttner S, Ruckenstuhl C, Carmona-Gutierrez D, Ring J, Schroeder S, Magnes C, Antonacci
L, Fussi H, Deszcz L, Hartl R, et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol. 2009; 11: 1305-1314.

95. Dang W, Steffen KK, Perry R, Dorsey JA, Johnson FB, Shilatifard A, Kaeberlein M, Kennedy BK, Berger SL. Histone H4 lysine 16 acetylation regulates cellular lifespan. Nature. 2009; 459: 802-807.

96. Kawahara TL, Michishita E, Adler AS, Damian M, Berber E, Lin M, McCord RA, Ongaigui KC, Boxer LD, Chang HY, Chua KF. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell. 2009; 136: 62-74.

97. Honjoh S, Yamamoto T, Uno M, Nishida E. Signalling through RHEB-1 mediates intermittent fasting-induced longevity in C. elegans. Nature. 2009; 457: 726-730.

98. Chen D, Thomas EL, Kapahi P. HIF-1 modulates dietary restriction-mediated lifespan extension via IRE-1 in Caenorhabditis elegans. PLoS Genet. 2009; 5: e1000486.

99. Mehta R, Steinkraus KA, Sutphin GL, Ramos FJ, Shamieh LS, Huh A, Davis C, Chandler-Brown D, Kaeberlein M. Proteasomal regulation of the hypoxic response modulates aging in C. elegans. Science. 2009; 324: 1196-1198.

100. Carrano AC, Liu Z, Dillin A, Hunter T. A conserved ubiquitination pathway determines longevity in response to diet restriction. Nature. 2009; 460: 396-399.

101. Curran SP, Wu X, Riedel CG, Ruvkun G. A soma-to-germline transformation in long-lived Caenorhabditis elegans mutants. Nature. 2009; 459: 1079-1084.

102. Soda K, Dobashi Y, Kano Y, Tsujinaka S, Konishi F. Polyamine-rich food decreases age-associated pathology and mortality in aged mice. Exp Gerontol. 2009; 44: 727-732.

103. ekli I, Ray D, Mukherjee S, Gurusamy N, Alhsan MK, Juhasz B, Bak I, Tosaki A, Gherghiceanu M, Popescu LM, Das DK. Coordinated autophagy with resveratrol and gamma-tocotrienol confers synergetic cardioprotection. J Cell Mol Med. 2009; In press.